Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
Polaryx Therapeutics, Inc PLYX
$1.96
▲ +1.03%
(+$0.02)
📅 Earnings This Week
Open
$1.97
Prev Close
$1.94
Day Range
$1.94 – $1.98
52W Range
$1.69 – $48.91
Market Cap
$96.70M
Beta
-1.13
EPS (TTM)
$-0.11
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-02 |
| Shares Out. | 49,850,000 |
| Website | polaryx.com/ ↗ |
| Phone | 12019407236 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.4M |
| Total Assets | $11.8M |
| Total Liabilities | $873,000 |
| Equity | $10.9M |
About Polaryx Therapeutics, Inc
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Polaryx Therapeutics, Inc is a publicly traded company under the ticker symbol PLYX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)